Erratum: Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma
Erratum to: Ann Transl Med 2021;9:332
The article (1) titled “Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma” (doi: 10.21037/atm-20-8093) unfortunately contains an error in Figure 5E. Two images of Figure 5E selected to represent the GAPDH expression in OGD treated PRNs detected by western blotting and Figure 6K selected to represent the GAPDH expression in PRNs subjected to OGD detected by western blotting after treatment with the M1 mAChR antagonists were duplicated accidentally. The legend of Figure 5 should be corrected as well.
Figure 5E and Figure 6K of the original article:
The correct version of Figure 5 and its legend are presented below:
The authors regretted the error and confirmed it did not significantly affect either the results or the conclusions of the paper.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Yu P, Dong WP, Tang YB, et al. Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma. Ann Transl Med 2021;9:332. [Crossref] [PubMed]